Market News Comments

Pfizer (PFE)

Pfizer announced the discontinuation of A4021016 (also known as ADVIGO 1016), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer due to the study meeting predefined boundaries for early termination.
An analysis by an independent Data Safety Monitoring Committee (DSMC) showed that the addition of figitumumab to paclitaxel plus carboplatin would be unlikely to meet the primary endpoint of improving overall survival compared to paclitaxel plus carboplatin alone.

Dec 31 · 1:36:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Enter your comment below and click Submit:

Copyright © 2010 MarketBeast.com.
All rights reserved.